InvestorsObserver
×
News Home

Should You Sell Aptevo Therapeutics Inc (APVO) in Biotechnology Industry?

Tuesday, June 14, 2022 01:53 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Sell Aptevo Therapeutics Inc (APVO) in Biotechnology Industry?

Aptevo Therapeutics Inc (APVO) is near the middle in its industry group according to InvestorsObserver. APVO gets an overall rating of 39. That means it scores higher than 39 percent of stocks. Aptevo Therapeutics Inc gets a 37 rank in the Biotechnology industry. Biotechnology is number 61 out of 148 industries.

Overall Score - 39
APVO has an Overall Score of 39. Find out what this means to you and get the rest of the rankings on APVO!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 39 would rank higher than 39 percent of all stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Aptevo Therapeutics Inc Stock Today?

Aptevo Therapeutics Inc (APVO) stock is trading at $3.38 as of 1:31 PM on Tuesday, Jun 14, a decline of -$0.15, or -4.25% from the previous closing price of $3.53. The stock has traded between $3.32 and $3.49 so far today. Volume today is 76,151 compared to average volume of 88,037. Click Here to get the full Stock Report for Aptevo Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App